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Abstract
Background: Highly active antiretroviral therapy (HAART) improves the immune function and decreases morbidity,
mortality and opportunistic infections (OIs) in HIV-infected patients. However, since the use of HAART, immune
restoration disease (IRD) has been described in association with many OIs. Our objective was to determine the
proportion of IRD, changes in CD4+ T-cell count and possible risk factors of IRD in HIV-infected patients.
Methods: A retrospective study of all HIV- infected patients starting HAART between September 1, 2005 and
August 31, 2006 at Zewditu memorial hospital HIV clinic, Addis Ababa, Ethiopia was conducted. All laboratory and
clinical data were extracted from computerized clinic records and patient charts.
Results: A total of 1166 HIV- infected patients with mean ± SD age of 36 ± 9.3 years were on HAART. IRD was
identified in 170 (14.6%) patients. OIs diagnosed in the IRD patients were tuberculosis (66.5%, 113/170),
toxoplasmosis (12.9%, 22/170), herpes zoster rash (12.9%, 22/170), Pneumocystis jirovecii pneumonia (4.1%, 7/170),
and cryptococcosis (3.5%, 6/170). Of the 170 patients with IRD, 124 (72.9%) patients developed IRD within the first
3 months of HAART initiation. Low baseline CD4+ T-cell count (odds ratio [OR], 3.16, 95% confidence interval [CI],
2.19-4.58) and baseline extra pulmonary tuberculosis (OR, 7.7, 95% CI, 3.36-17.65) were associated with
development of IRD. Twenty nine (17.1%) of the IRD patients needed to use systemic anti-inflammatory treatment
where as 19(11.2%) patients required hospitalization associated to the IRD occurrence. There was a total of 8 (4.7%)
deaths attributable to IRD.
Conclusions: The proportion and risk factors of IRD and the pattern of OIs mirrored reports from other countries.
Close monitoring of patients during the first three months of HAART initiation is important to minimize clinical
deterioration related to IRD.
Background
Highly active antiretroviral therapy (HAART) improves
the immune function and decreases morbidity, mortality
and opportunistic infections (OIs) in HIV-infected
patients [1,2]. However, the introduction of HAART
presents new clinical problems, including adverse drug
effects, and the event of diseases that are as the result of
the restoration of the immune response. When clinical
deterioration occurs during immune recovery and is
associated with the host inflammatory response to
pathogens, the clinical presentation has been described
as immune restoration disease (IRD), immune reconsti-
tution inflammatory syndrome or immune reconstitu-
tion disease [3,4].
IRDs usually occur within a few weeks to months after
the initiation of HAART and majority of patients with
IRD present with unusual manifestations of OIs, most
often while the number of CD4+ T lymphocytes is
increasing and the viral load is decreasing [5,6]. Even if
no consistent definition exists for IRD, its diagnosis
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unrecognized (unmasking) pre-existing infection in the
setting of improving immunologic function [7].
Previous studies of IRD in association with initiations
of HAART to treat HIV infection differ widely and
reports have indicated IRD ranges from 10-30% in
patients who started HAART [8-10]. Majority of IRDs
described in adults are commonly reported in associa-
tion with Mycobacterium tuberculosis (MTB), a major
cause of morbidity and mortality among patients living
with HIV/AIDS worldwide [11,12]. IRD has also been
associated with a range of OIs, including cytomegalo-
virus, hepatitis B and C viruses, Pneumocystis jirovecii,
Cryptococcus neoformans, herpes viruses, progressive
multifocal leucoencephalopathy, leishmaniasis, and cere-
bral toxoplasmosis [12].
In Ethiopia, antiretroviral therapy (ART) has been
made available to HIV/AIDS patients since 2004.
Although over 250,000 HIV/AIDS patients require ART
in the country, only 24% of the eligible adults were on
ART by the end of 2007 [13]. Studies on IRDs and
Changes in CD4+ T-cell count among HIV- infected
patients during HAART in Ethiopia are very scarce.
Therefore, retrospective study was conducted to deter-
mine the proportion of IRD, changes in CD4+ T-cell
count and possible risk factors of IRD during HAART.
Methods
All HIV- infected subjects (≥18 years) who were seen at
Zewditu memorial hospital HIV clinic, Addis Ababa,
Ethiopia between September 1, 2005 and August 31,
2006 and who were naive to antiretroviral-treatment at
t h et i m et h e ys t a r t e dH A A R Tw e r er e t r o s p e c t i v e l y
recruited. Patients who did not have adherence to
HAART, who had previous antiretroviral exposure and
subjects with incomplete clinical and laboratory data
were excluded from the study. The hospital ethical
review board and national ethical committee approved
the protocol. Treatment initiation was in compliance
with Ethiopian National Antiretroviral Treatment
Guidelines [13]. The HAART was a combination of tri-
ple regimen with 2 nucleoside reverse-transcriptase inhi-
bitors and a non- nucleoside reverse-transcriptase
inhibitor.
After initiation of HAART, the study subjects were
followed every 0.5, 1, 2, 3, 6, 9 and 12 months for any
clinical complaints during the study period. Socio-demo-
graphic characteristics, previous clinical data, HAART,
CD4+ T-cell count, white blood cell (WBC) count,
hemoglobin (Hgb) level, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and alkaline
phosphatase (ALP) values were collected from compu-
terized clinic records and patient charts at the initiation
and 6 months of HAART time. Moreover, two senior
physicians reviewed the patients’ chart records to iden-
tify any clinical events (IRD) after commencing HAART
(including date of onset, diagnostic methods, clinical
history, etc).
With freshly collected blood samples, CD4+ T-cell
count (cells/μl) was determined using FACSCount appa-
ratus (Becton Dickinson, Sparks, MD., USA) following
the manufacturer’s protocol. WBC count (cells/μl), Hgb
level (gm/dl), and ALT, AST and ALP (IU/L) values were
also determined following the standard procedures [14].
Sputum or aspirates were collected from patients with
clinical features suggestive of tuberculosis (TB).TB was
diagnosed by smear microscopy to detect acid-fast
bacilli (AFB), chest X-ray and/or Ultrasonic and clinical
methods.
Diagnosis of cryptococcosis was based on laboratory
and clinical features of the organism. Cerebrospinal fluid
was examined microscopically for the detection of cryp-
tococcal capsule using Indian ink following the standard
procedure [14]. Toxoplasmosis was diagnosed by detect-
ing immunoglobulin G using Enzyme-linked immuno-
sorbent assay in addition to its clinical features and
Pneumocystis jirovecii pneumonia (PCP) was identified
using clinical and chest X-ray assessments and herpes
zoster rash was diagnosed by clinical examination.
Diagnosis of IRD was based on previously published
definitions [15-18]. In brief, subjects with HIV infection,
low CD4+ T-cell count at baseline (most of the patients
had < 90 CD4+ T-cell count/μl), and clinical symptoms
consistent with inflammatory process after starting
HAART considered to have developed IRD. Since viral
load determination was not available in the country, it
was not used as criterion to diagnose IRD. Patients who
developed IRD were treated and managed as per routine
clinical practice of the HIV clinic.
All data were entered and analyzed using SPSS version
15 packages (SPSS, Chicago,II., USA). Student’st - t e s t
and chi-square tests were employed for analysis of con-
tinuous and categorical data, respectively. Risk factors
related to the development of IRD following HAART
initiation were identified using binary logistic regression
analyses and a p value of less than 0.05 was considered
statistically significant.
Results
A total of 1166 HIV- infected patients with mean ± SD
age of 36 ± 9.3 year were included for this retrospective
study. Majority of the patients were females (55.3%) and
married (47.7%). Most of the study subjects had history
of previous OIs and the predominant OIs investigated
were herpes zoster rash (43.2%) followed by TB (27.6%).
At time of HAART initiation, the patients were also
diagnosed for OIs and the majority of the patients had
candidiasis (37%) followed by TB (22.1%) (Table 1).
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Page 2 of 7At time of HAART initiation, the mean ± SD of CD4+
T-cell count, WBC count and Hgb value of the total 1166
subjects, respectively, were 113.6 ± 71, 47671 ± 1824,
12 ± 2.4 and 28%, 23.6%, and 22.9% of the patients had an
elevated AST, ALT, and ALP, respectively. According to
the WHO AIDS clinical staging criteria, 55.7%, 31.7%,
11.4% and 1.2% of the patients, respectively, were classi-
fied under stage III, stage IV, stage II and stage I and the
predominant HAART regimen given was 1b (combination
of lamivudine, stavudine ande f a v i r e n z )f o l l o w e db y1 a
(combinations of lamivudine, stavudine and nevirapine),
1d (combination zidovudine, lamivudine and efavirenz)
and 1c (combination of zidovudine, lamivudine and
nevirapine) for 34%, 23.3%, 22% and 20.6% of the patients,
respectively at time of HAART initiation.
One hundred seventy (14.6%) of the study subjects
developed IRD. Table 2 shows the baseline characteris-
tics of patients with and without IRD. The patients with
IRD at HAART initiation were younger, had low CD4+
T-cell count, low WBC count and higher proportion of
extra pulmonary tuberculosis(EPTB) (P <0 . 0 5 ) .H o w -
ever, there were no significantly differences in body
weight, regimen, marital status, gender, pulmonary
tuberculosis (PTB) and disseminated tuberculosis (DTB)
between patients with and without IRD (P > 0.05). The
interval between the start of HAART and the onset of
Table 1 Pattern of past opportunistic infections and opportunistic infections at time of HAART initiation in
HIV- infected patients, at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
Types of previous OIs Frequency (%) Types of OIs at time of HAART initiation Frequency (%)
Herpes zoster 504 (43.2) Candidiasis 431 (37.0)
PTB 236 (20.2) PTB 150 ( 12.9)
EPTB 83 (7.1) EPTB 64 (5.5)
DTB 3 (0.26) DTB 44 ( 3.8)
Candidiasis 189 (16.2) Toxoplasmosis 30 (2.6)
PCP 36 (3.1) Herpes zoster 20(1.7)
Toxoplasmosis 35 (3.0) PCP 7 (0.6)
Cryptococcosis 30(2.6) Herpes simplex 2 (0.17)
Herpes simplex 14 (1.2) Total 748 ( 64.2)
Total 1130(96.9%)
Keys: OI, opportunistic infection; HAART, highly active antiretroviral therapy; PTB, pulmonary tuberculosis; EPTB, extra pulmonary tuberculosis; DTB, disseminated
tuberculosis; PCP, Pneumocystis jirovecii pneumonia.
Table 2 Baseline characteristics of study subjects at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
Characteristic Patients with IRD (n = 170) Patients without IRD (n = 996) P-value
Age(years),mean ± SD 33.9 ± 7.7 36.4 ± 9.5 0.001
Body weight (kg), mean ± SD 48.5 ± 7.3 50.7 ± 15.5 0.13
CD4+ (cells/μl), mean ± SD 84 ± 57.8 116 ± 69.4 <0.001
WBC(cells/μl),mean ± SD 4246 ± 1948 4814 ± 1729 <0.001
HAART regimens (%)
Lamivudine/Stavudine/Efavirenz 31.7 34.4 0.50
Lamivudine/Stavudine/Nevirapine 27.1 22.7 0.21
Zidovudine/Lamivudine and Efavirenz 21.8 22.1 0.92
Zidovudine/Lamivudine/Nevirapine 19.4 20.8 0.68
Marital status (%)
Single 28.8 31.9 0.42
Married 47.0 49.1 0.62
Divorced 11.8 9.2 0.30
Widowed 12.4 9.7 0.30
Gender (%)
Male 49.4 43.9 0.18
Female 50.6 56.1
Site of TB (%)
PTB 29.4 33.7 0.27
EPTB 52.4 5.8 <0.001
DTB 4.7 3.9 0.63
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Page 3 of 7IRD was variable and ranged from 11 to 329 days with a
mean ± SD of 96 ± 89 days. Majority (72.9%) of the
patients developed IRD within the first three months of
HAART initiation (Figure 1).
Of the 170 IRD cases, 132 (77.6%) were new presenta-
tions (unmasking) and the 38 (22.4%) were due to wor-
sening of a recognized infections (paradoxical). The
most frequent OI associated with IRD in the study was
TB (66.5%, 113/170) of which 47.8% (54/113), 46% (52/
113) and 6.2% (7/113) were EPTB, PTB and DTB,
respectively. Sixty nine point nine percent (79/113) of
TB episodes were new presentations (PTB (57%, 45/79),
EPTB (39.2%, 31/79) and DTB (3.8%, 3/79), and 30.1%
(34/113) cases were due to worsening of a recognized
infection (EPTB (67.6%, 23/34), PTB (20.6%, 7/34) and
DTB (11.8%, 4/34)). Of the total TB/IRD patients 54%
were positive for AFB and the source of specimens were
from sputum (67%) and fine needle aspiration (33%).
IRDs other than TB/IRD were toxoplasmosis (12.9%,
22/170), herpes zoster rash (12.9%, 22/170), PCP (4.1%,
7/170), and cryptococcosis (3.5%, 6/170), and the
unmasking infections involved were toxoplasmosis (22/
170), herpes zoster rash (22/170), cryptococcosis (6/170)
and PCP (3/170).
AIDS clinical stage shift was observed in 27.6% (47/
170) of the IRD patients: 32 from clinical stage III to IV,
11 from clinical stage II to III, and 4 from clinical stage
II to IV. Treatment shift was also observed in 21.2%
(36/170) of the IRD patients, 7 from 1a to 1b, 6 from 1c
to 1d, 5 from 1a to 1c, 5 from 1b to 1c, 4 from 1b to
1d, 3 from 1a to 1d, 3 from 1c to 1a, 2 from 1d to 1b,
and 1 from 1b to 1a.
There was also a treatment shift in 6.6% (66/996) of
the non IRD patients due to peripheral neuropathy
(3.3% from 1b to 1d and 3.3% from 1a to 1c). Three
point one percent (31/996) and 1.6% (16/996) of the
non IRD patients had developed severe anemia (with a
Hgb value of less than 6.9 gm/dl) and hepatotoxicity,
respectively. Forty percent of the non-IRD patients had
developed anemia with a Hgb value of less than or
equal to 11 gm/dl.
For all study subjects, six months after initiation of
HAART, the mean ± SD CD4+ T-cell count (230 ±
118), Hgb value (13.2 ± 3.8) and WBC count (6409 ±
1998), showed statistically significant elevation from the
values at HAART initiation (P < 0.001). In addition,
34.5%, 31.4% and 26% of patients had significantly ele-
vated values of AST, ALT and ALP respectively com-
pared to the values at the initiation of HAART (P <
0.001). At nine months after initiation of HAART, both
IRD (73%) and non IRD (27.4%) patients had a third
CD4+ T-cell count with mean ± SD values of 220 ±
0
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Figure 1 Time (days) to diagnosis of IRD after initiation of HAART.
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Page 4 of 797.3 and 292 ± 145.6, respectively. The trend in CD4+
T-cell count changes versus number of months of treat-
ment in patients with and without IRD is shown in
Figure 2.
After commencement of HAART, laboratory values of
patients with and without IRD were compared and there
were significant increases in CD4+ T-cell count, WBC
count, ALT and AST in IRD and non IRD patients, and
ALP and Hgb values in non IRD patients (P <0.05)
(Table 3).
Of the IRD patients 17.1% (29/170) needed to use sys-
temic anti-inflammatory treatment to alleviate symp-
toms of IRD. There were eight deaths attributable to
IRD and the causes of deaths were PTB, EPTB and DTB
in 3, 3, and 2 of them, in that order. The mean ± SD
baseline CD4+ T-cell count for these who died of IRD
was 46 ± 17.6 and 19(11.2%) of IRD patients required
hospitalization associated to their IRD occurrence.
Binary logistic regression was employed to assess if
age, CD4+ T-cell count, WBC count, PTB, EPTB and
DTB are possible risk factors for development of IRD.
Low CD4+ T-cell counts (odds ratio [OR], 3.16, 95%
confidence interval [CI], 2.19-4.58) and EPTB (OR, 7.7,
95% CI, 3.36-17.65) were found to be risk factors for
development of IRD.
Discussion
HAART improves immune function by suppressing HIV
viral replication and increasing CD4+ T-cell counts [19].
Since its usage, IRD has been described in association
with many concomitant infections such as mycobacterial,
fungal and viral infections. In this retrospective study,
from 1166 HIV/AIDS patients treated with HAART dur-
ing the defined period of time, the proportion of IRD was
14.6% (170/1166). This finding is consistent with studies
done elsewhere where the occurrence of IRD was
between 10% - 25% [3,5,8,9,20,21]. In this study most of
the IRD cases occurred within the first three months of
HAART initiation, which is in agreement with prior
reports [3,9,10].
Of the 170 IRD cases, 77.6% were new presentations,
and 22.4% were due to paradoxical episodes. This report
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Figure 2 Changes in CD4+ T-cell count for IRD (cases) and non IRD (non cases) patients versus number of months of treatment.
Table 3 Laboratory values of patients with and without immune restoration disease before and after HAART
commencement, at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
Variables Patients with IRD (n = 170) Patients without IRD (n = 996)
Mean (SD) values
at baseline
Mean (SD) values
after 6 months
P-value Mean (SD) values
at baseline
Mean (SD) values
after 6 months
P-value
CD4+ (cells/μl) 84 (57.8)* 185(94.8) 0.001 116 (69.4) 236(120) 0.001
WBC (cells/μl) 4246(1948) 5725 (3124) 0.001 4814 (1729) 6516(2072) 0.001
Hgb (gm/dl) 11.5(2.9) 12.1 (4.7) 0.400 12.2 (2.7) 13.9 (3.8) 0.001
AST (IU/L) 30.7(23.2) 37.8(28.8) 0.020 30(25.7) 43 (34.2) 0.001
ALT (IU/L) 25.3(20.2) 33.4(28.9) 0.003 25.1(23) 39 .2(34) 0.001
ALP (IU/L) 208(160) 213(167) 0.770 190 (149.9) 251 (212) 0.001
* Mean (SD); IRD, immune restoration disease; WBC, white blood cell; Hgb, hemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP,
alkaline phosphatase.
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Our finding of TB/IRD in majority of the IRD patients
(9.7%) is in accordance with studies conducted in India,
Thailand and Texas in which 7.6%, 12.6% and 14.4%
IRD was caused by MTB [2,10,22]. However, our report
is relatively low as compared with studies done in
Thailand and Texas. Our low rate of MTB infection
might be explained partly due to genetic polymorphism
and racial differences of the study subjects [23]. And the
nature of retrospective studies that may result differences
in documenting and interpreting data in different settings
also might play a role in variation of IRD reports.
In the study, 1.9% (22/1166) of the patients developed
herpes zoster rash with mild and uncomplicated clinical
manifestation. This finding is not consistent with a pre-
vious study in which a relatively high proportion of
herpes zoster rash was indicated [8]. This variation may
be due to the nature of our retrospective study. Soon
after the initiation of HAART, it was observed that
some patients presented with initial or recurrent episode
of cryptococcal meningitis during the first weeks to
months of therapy [24]. In the current study, cryptococ-
cal meningitis was observed in 0.5% (6/1166) of the
study subjects. This finding is in agreement with a pre-
vious study conducted somewhere else [8]. However, the
report is low compared to a study conducted in France
in which 8.3% cryptococcosis associated IRD was
reported [25]. This discrepancy might be due to the dif-
ference in method employed for diagnosing of
cryptococcosis.
In the study, 1.9% (22/1166) of the subjects developed
toxoplasmosis and this figure is similar compared to the
previous study [20]. In addition, 0.6% (7/1166) of the
patients had developed PCP and this is comparable with
a study conducted elsewhere [9].
In comparison with patients who did not develop IRD,
the IRD patients had significantly low CD4+T- cell
count and WBC count, and higher proportion of EPTB
and younger age at baseline (P < 0.05). However, in bin-
ary logistic regression analyses low CD4+ T-cell count
and EPTB were found to be risk factors for development
of IRD. Previous studies also described that both low
baseline CD4+ T-cell count and EPTB as the possible
risk factors that were associated with the occurrence of
IRD [22,26].
Thirty-one (3.1%, 31/996) patients had developed
severe anemia with Hgb value below 6.9 gm/dl [27].
T h i sm i g h tb ed u et ot h en a t u r eo fs o m ea n t i r e t r o v i r a l
drugs which have myelosuppressive effect, especially
with respect to the red blood cells which eventually lead
to the development of anemia [28]. Sixteen (1.6%,16/
996) of the study subjects also developed hepatotoxicity
with three to five fold increments in serum levels of
AST and ALT. This finding is in accordance with a
study conducted by Becker [29]. This might be due to
the direct effect of antiretroviral drugs, mainly nevira-
pine, that induce the development of hepatotoxicity
[30]. Consistent with a previous report [8], in the pre-
sent study we observed a 4.7% mortality rate after initia-
tion of HAART among IRD patients.
Conclusions
In this retrospective study, 14.6% of the patients had
clinical deterioration (IRD) during immune recovery and
eight deaths were attributable to IRD. Most IRDs were
observed within the first three months of HAART initia-
tion, primarily affecting patients with lower baseline
CD4+ T-cell counts and the majority of IRD cases were
TB/IRD. Low baseline CD4+ T-cell count and EPTB
were associated with development of IRD. Therefore,
strict following of patients during the first three months
of HAART initiation and diagnosis of latent TB [31]
would help to prevent complications related to TB/IRD.
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